Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.60 +0.88 (+1.87%)
Streaming Delayed Price Updated: 2:51 PM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
36 37 Next >
News headline image
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
News headline image
Healthcare Gems: 3 Essential Long-Term Stock Picks ↗
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
News headline image
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics ↗
Shareholders will do well to prepare themselves for how regulators might react. 
Via The Motley Fool
News headline image
Is This News a Setback or a Step Forward for CRISPR Therapeutics? ↗
It's important to look at the news through a long-term lens. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
5 Unstoppable Trends to Invest $1,000 in for 2024 ↗
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year. 
Via The Motley Fool
News headline image
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
News headline image
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases ↗
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T  
Via Benzinga
News headline image
Better Growth Stock: CRISPR Therapeutics vs. Invitae ↗
One of these stocks may be riskier than the other... 
Via The Motley Fool
News headline image
The Market's Up This Year. Do You Feel Like You Are Winning? ↗
We've also got a look at two stocks worth watching and the popular toys for this holiday season. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics the Best Gene-Editing Stock? ↗
The biotech's first-mover advantage bodes well for its long-term prospects. 
Via The Motley Fool
News headline image
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
News headline image
Where Will Vertex Pharmaceuticals Be in 10 Years? ↗
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
News headline image
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today ↗
CRISPR Therapeutics' shares advanced in the double-digits this year. 
Via The Motley Fool
News headline image
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now ↗
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool
News headline image
An Important History Lesson for Gene-Editing Investors ↗
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy Before 2024 ↗
These stocks have room to run -- next year and over the long term. 
Via The Motley Fool
News headline image
Five Best Performing Stocks Of The Top ETF Of November ↗
Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way. 
Via Talk Markets
Topics ETFs
News headline image
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
It's not as long a shot as some might think. 
Via The Motley Fool
News headline image
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist ↗
These stocks offer enormous long-term growth potential. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making ↗
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
News headline image
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014. 
Via Benzinga
Topics ETFs
News headline image
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. 
Via Benzinga
News headline image
3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
News headline image
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market ↗
These stocks may take off in a market favoring growth. 
Via The Motley Fool
News headline image
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree ↗
These innovators should have tremendous long-term growth prospects. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Could Be Millionaire Makers ↗
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.